Document:

Prepared by R.R. Donnelley Financial -- EX-10.4

 Exhibit 10.4 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 CONFIDENTIAL 

NON-EXCLUSIVE LICENSE AGREEMENT 

[“Cabilly Patents”] 

This Non-Exclusive License Agreement (“Agreement”) is effective as of July 10, 2013 (“Effective Date”)
by and between Genentech, Inc., a corporation having its principal place of business at 1 DNA Way, South San Francisco, California 94080 (hereinafter “Genentech”) and Coherus Biosciences, Inc., a corporation having its principal
place of business at 201 Redwood Shores Parkway, Suite 200, Redwood City, CA 94065 (hereinafter “Coherus”). 
 WHEREAS:

  

	 	A.	Genentech owns and controls certain patent rights relating to methods and compositions in the field of antibodies (the “Licensed Patents”, as that term is defined below); 

 

	 	B.	Coherus is developing, and intends to commercialize, including through Affiliates, an antibody product that binds to the Antigen (as defined below) and wishes to acquire a non-exclusive license to commercialize such
product and related products under the Licensed Patents; and 

  

	 	C.	Genentech is willing to grant such a non-exclusive license to Coherus on the terms and conditions set forth below. 

NOW, THEREFORE, in consideration of the promises and the mutual covenants recited herein, the Parties agree as follows: 

ARTICLE I 
 DEFINITIONS 

Unless otherwise specifically set forth herein, the following terms shall have the following meanings: 

1.01 “Affiliate” shall mean any corporation or other entity which, directly or indirectly, controls, is controlled by or is
under common control with, a Party. For the purpose of this Section 1.01 “control” shall mean (i) the ownership, directly or indirectly, of at least fifty percent (50%) of the outstanding voting securities or other ownership
interest of an entity, or (ii) the possession, directly or indirectly, of the power to manage, direct or cause the direction of the management and policies of the corporation or other entity or the power to elect or appoint fifty percent
(50%) or more of the members of the governing body of the corporation or other entity. 
 1.02 “Antibody” shall mean
any antibody that specifically binds the Antigen, including, without limitation, full-length antibodies and antibody fragment forms, such as Fv, Fab and F(ab’)2 , and antibodies or fragments thereof conjugated to a toxin, drug, label or other

 
moiety. Antibody shall not include any bi-specific antibody, antibody form thereof, or conjugate thereof. [***]. 

1.03 “Antigen” shall mean Tumor Necrosis Factor alpha. 

1.04 “Calendar Quarter” shall mean each three month period commencing January 1, April 1, July 1 and
October 1 of each year during the Term. 
 1.05 “City of Hope” shall mean the City of Hope, having a place of business
at 1500 E. Duarte Road, Duarte, CA 91010. 
 1.06 “Combination Product” shall mean (a) either a single pharmaceutical
formulation containing as its active ingredients both an Antibody and one or more other therapeutically or prophylactically active ingredients, or (b) a combination therapy comprised of an Antibody and one or more other therapeutically or
prophylactically active products, priced and sold in a single package containing such multiple products, in each case, in all dosage forms, formulations, presentations, line extensions, and package configurations. All references to Licensed Product
in this Agreement shall be deemed to include Combination Product. 
 1.07 “Designee(s)” shall mean any corporation or other
entity that is not an Affiliate designated by and under written contract with Coherus or its Affiliates to exercise the license rights of Coherus hereunder in concert with, or in place of and to the exclusion of, Coherus and its Affiliates in all or
part of the Territory. 
 1.08 “Field of Use” shall mean the diagnosis, prevention, control and/or treatment of any and all
therapeutic conditions. 
 1.09 “First Commercial Sale” shall mean the first sale of any Licensed Product by Coherus, its
Affiliate or a permitted Sublicensee thereof to a Third Party. The sale shall be deemed to occur on the date of the invoice to the Third Party for the Licensed Product. 

1.10 “Licensed Patents” shall mean (i) U.S. Patent No. 6,331,415, issued December 18, 2001 from USSN
07/205,419, (ii) any unexpired patent(s) issuing from divisionals, continuations, or continuations-in-part of any patent application from which U.S. Patent No. 6,331,415 claims priority, including USSN 08/422,187, and (iii) patents
that are reissues, reexaminations or extensions of any of the foregoing subsections (i) or (ii), and (iv) foreign counterparts of any of the foregoing subsections (i), (ii) or (iii). 

1.11 “Licensed Product” shall mean any product containing an Antibody, the making (or having made), using, selling, offering
for sale or importing of which, but for the license granted under this Agreement, would infringe a Valid Claim in the country or jurisdiction in which such activity occurs. 

1.12 “Marketing Approval” shall mean all approvals, licenses, registrations or authorizations of any regulatory agency,
department, bureau or other governmental entity, necessary for the manufacturing, use, storage, import, transport, marketing and sale of Licensed Products in a country or regulatory jurisdiction. 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 2 

 “Net Sales” of Licensed Product in a particular period shall mean [***].

 1.13 “Party” shall mean either Genentech or Coherus, and when used in the plural shall mean both Genentech and Coherus.

  
 [***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 3 

 1.14 “Royalty Term” shall mean, with respect to Licensed Product, on a
country-by- country basis, the period of time beginning on the First Commercial Sale and ending on the date of expiration of the last Valid Claim. 

1.15 “Sublicensee” is defined in Section 2.02. 

1.16 “Term” is defined in Section 7.01. 

1.17 “Territory” means the entire world. 

1.18 “Third Part(y)ies” means any part(y)ies other than Coherus, Affiliates thereof and Designees. 

1.19 “Third Party Contractor” means a Third Party to whom Coherus, its Affiliate or a Sublicensee contracts to perform
activities to facilitate the development or marketing of a Licensed Product on behalf of Coherus, an Affiliate thereof or a Sublicensee, including without limitation, to manufacture, fill, finish, distribute and/or ship Licensed Product. 

1.20 “U.S.” and “United States” shall mean the United States of America, including its territories and
possessions. 
 1.21 “Valid Claim” shall mean any claim of an issued and unexpired patent within the Licensed Patents that
has not been disclaimed, abandoned or dedicated to the public or held unenforceable, unpatentable or invalid by a decision of a court or governmental agency of competent jurisdiction, which decision is unappealable or unappealed within the time
allowed for appeal. 
 1.22 “Valid Sublicense Product” shall mean a specific Coherus proprietary Licensed Product for which
Coherus or its Affiliates have exclusive rights to make, sell, offer for sale, import and export worldwide. 
 ARTICLE II 

GRANT 
 2.01 License.
Genentech hereby grants to Coherus and Coherus hereby accepts a non- exclusive license under the Licensed Patents during the Term to make (and have made), use, sell, offer for sale, and import Licensed Product in the Territory in the Field of Use.
Coherus shall have a limited right to grant sublicenses with respect to Valid Sublicense Product as provided in Section 2.02. 

2.02 Right to Grant Sublicenses. Coherus shall only have the right to grant sublicenses to its Affiliates and Designees (each a
“Sublicensee”) of the rights granted hereunder to Coherus to make (and have made), use, sell, offer for sale, and import Valid Sublicense Product, in all or any part of the Territory; provided that Coherus shall always be
responsible for the payment of royalties on Net Sales of Valid Sublicense Product by any such Sublicensee and for all other obligations of such Sublicensee under this Agreement as if such obligations were those of

  
 4 

 
Coherus. The right to grant a sublicense hereunder to a Sublicensee shall be contingent upon, and shall be effective and valid only in the event such sublicense contains provisions binding such
Sublicensee that are substantially and effectively the same as the provisions of this Agreement, including, without limitation, the grant to Coherus of audit rights similar to Genentech’s audit rights under Section 4.01 of this
Agreement, which rights Coherus agrees to exercise for Genentech at Genentech’s request and expense. Coherus and its Affiliates shall notify Genentech in writing promptly after the grant of a sublicense hereunder to any Designee (including in
such notice the name and address of the Designee). A sublicense granted under this section shall only be further sublicensed in connection with Valid Sublicense Product. 

2.03 Third Party Contractors. Coherus, its Affiliates and/or Sublicensees shall be permitted to contract with a Third Party Contractor,
provided such Third Party Contractor shall only have the right to perform activities on behalf of Coherus, its Affiliate and/or Sublicensee, shall have no right under the license granted hereunder to use Licensed Product in any other way and shall
have no right to sell, offer for sale, import or export Licensed Product. 
 2.04 No Other License. Coherus understands and agrees
that no license under any patent or patent application other than Licensed Patents, or under any know-how, is or shall be deemed to have been granted under this Agreement, either expressly or by implication. 

ARTICLE III 
 FEES AND ROYALTIES

 3.01 License Grant Fee. Coherus shall pay to Genentech a one-time, non-creditable, non-refundable license grant fee of
[***]. 
 3.02 Development Milestone Payment. Coherus or its Affiliate shall pay a development milestone payment to Genentech
for the first Licensed Product to achieve the development milestone event set forth below. Coherus or its Affiliate shall notify Genentech in writing within fifteen (15) calendar days of achieving such event, and Coherus or its Affiliate shall
make the development milestone payment to Genentech within thirty (30) calendar days of achieving such event. 
 (i) For
[***], Coherus shall pay to Genentech a one-time, non-creditable, non-refundable development milestone fee of [***]; the development milestone payment set forth in this section shall be payable only one time and only with respect to the first
Licensed Product to achieve such milestone event, regardless of how many Licensed Products subsequently achieve such milestone event. 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  
 5 

 (b) Royalties. For sales of Licensed Product occurring after the First Commercial Sale,
Coherus or its Affiliates shall pay to Genentech on a Calendar Quarter basis a royalty as follows: [***]. 
 3.03 Sales To or
Between Coherus, Affiliates and Sublicensees. It is the intent of the Parties that Net Sales shall be based on arm’s length sales transactions to Third Parties. No royalties shall be paid upon sales of Licensed Product to or among any of
Coherus, its Affiliates and Designees for further sale; provided, however, that in such cases royalties shall be paid upon such further sale of Licensed Product by Coherus, its Affiliates or Sublicensees to Third Parties. 

3.04 No Non-Monetary Consideration. Without the prior written consent of Genentech, Coherus, its Affiliates and Sublicensees shall not
solicit or accept any consideration for the sale of any Licensed Product unless such consideration will be accurately reflected in Net Sales. 

3.05 No Credit Against Royalties. Coherus shall not be entitled to deduct any portion of royalties or other amounts paid to any Third
Party from the fees or royalties due to Genentech pursuant to this Agreement for any reason. 
 ARTICLE IV 

RECORDS, REPORTS AND PAYMENTS 

4.01 Records Retention. Coherus shall keep and shall cause its Affiliates and Sublicensees to keep true, complete and accurate records
of all sales of all Licensed Product in accordance with GAAP, or the equivalent, and in sufficient detail to confirm the accuracy of Coherus’ royalty calculations. Such records shall be kept for [***] following the end of the calendar
year to which they pertain or as required for a requested examination of such records as set forth below. At Genentech’s request and expense, Coherus shall permit, not more than once in a calendar year, an independent certified public
accountant appointed by Genentech and acceptable to Coherus to examine at Coherus’ principal places of business, upon reasonable notice and at reasonable times, such records solely to the extent necessary to verify Coherus’ calculations.
Coherus shall be responsible for providing access to such records as in the ordinary course of business that are in the possession or control of its Affiliates and Sublicensees. Such examination shall be limited to a period of time no more than
[***] immediately preceding the request for examination. The report of any such examination shall be made simultaneously to Coherus and Genentech, and the report shall state the amount, if any, by which Coherus has overpaid or underpaid its
royalties, including an explanation of such overpayment or underpayment and all data and calculations used to arrive at such overpayment or underpayment. If the royalties paid are found to be in error such that royalties to Genentech were underpaid,
then Coherus shall pay the deficient amount plus interest pursuant to Section 4.05 to Genentech 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  
 6 

 
within thirty (30) calendar days of delivery of the final audit report; and if royalties to Genentech were underpaid by more than [***] of the total royalty owed for the period in
question, then Coherus shall additionally reimburse Genentech for its reasonable costs incurred in examining such records. If the underpayment is less than [***] of the total royalty owed for the period in question, Coherus shall only be
obligated to pay the deficient amount plus interest pursuant to Section 4.05 to Genentech within thirty (30) calendar days of delivery of the final audit report. If Coherus’ royalties are found to be in error such that
royalties to Genentech were overpaid, then such overpayment shall be credited against future royalty payments to Genentech. Amounts credited by Genentech against future royalty payments shall not exceed the amount of overpayment for the audit
period. Genentech shall treat the report under this Section 4.01 in accordance with the confidentiality provisions of this Agreement, and shall cause its independent certified public accountant to enter into a confidentiality agreement
with and acceptable to Coherus obligating the independent certified public accountant to retain all such information in confidence pursuant to such confidentiality agreement. 

4.02 Reports. Within sixty (60) calendar days after the end of each Calendar Quarter following the First Commercial Sale of
Licensed Product, Coherus shall provide to Genentech a written report of all Net Sales subject to royalty under Article III during such Calendar Quarter. Such report shall include, on a country-by-country basis, the determination of Net
Sales, setting forth without limitation, the amount of gross sales, deductions taken from gross amount invoiced for sales to arrive at Net Sales and Net Sales amounts, and the royalty payment due. 

4.03 Payments. Concurrently with each report pursuant to Section 4.02, Coherus shall make the royalty payment then due.
Payments shall be in United States dollars and, unless otherwise agreed in writing, shall be made by wire transfer of immediately available funds to such account of Genentech in such bank as Genentech may from time to time designate in writing. All
royalty payments shall be free and clear of any taxes, duties, levies, fees or charges, except for withholding taxes. Coherus shall pay any withholding tax due on behalf of Genentech, and such withholding taxes shall be deducted from all payments
due hereunder. The Parties shall cooperate to take advantage of the benefit of any double taxation treaty(ies) that may be applicable. 

4.04 Currency Conversion. Royalties payable on Net Sales of Licensed Product made in currency other than U.S. dollars shall be
expressed in the currency of the invoice issued by the party making the sale together with the U.S. dollar equivalent of the royalty payable, calculated using the method consistently applied by Coherus in preparing its audited financial statements.

 4.05 Interest. All payments not made when due shall bear interest, calculated from the date such payment was due, at [***].

  
 [***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 7 

 ARTICLE V 

REPRESENTATIONS AND WARRANTIES 

5.01 Genentech represents and warrants that it has the full right, power and authority to enter into this Agreement and to grant the license
granted under this Agreement. Genentech represents and warrants that (a) it is the co-owner, with the City of Hope, of the Licensed Patents, and (b) by virtue of an agreement between Genentech and the City of Hope, Genentech has the
exclusive right to grant licenses under the Licensed Patents, including the right to grant the license granted under this Agreement. 
 5.02
Each Party represents and warrants that it has made such investigation of all matters pertaining to this Agreement as such Party deems necessary, and does not rely on any statement, promise, or representation, whether oral or written, with respect
to such matters other than those expressly set forth herein. Each Party agrees that it is not relying on any matter or any statement, promise, or representation, whether oral or written, made by any person or entity, not specifically set forth in
this Agreement. 
 5.03 Nothing in this Agreement is or shall be construed as: 

(i) A warranty or representation by Genentech as to the validity, enforceability, patentability or scope of any claim or patent
or patent application within the Licensed Patents; 
 (ii) A warranty or representation by Genentech that anything made,
used, sold, or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of any patent rights or other intellectual property right of any Third Party; 

(iii) A grant by Genentech, whether by implication, estoppel, or otherwise, of any licenses or rights other than that expressly
granted under Section 2.01; or 
 (iv) An obligation to bring or prosecute actions or suits against any Third Party for
infringement of any of the Licensed Patents. 
 5.04 EXCEPT AS SET FORTH IN THIS ARTICLE, NO WARRANTY IS GIVEN WITH RESPECT TO THE LICENSED
PATENTS, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUE OR OTHERWISE, AND THE PARTIES SPECIFICALLY DISCLAIM ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY, ENFORCEABILITY,
PATENTABILITY, SCOPE AND/OR INFRINGEMENT OF THE LICENSED PATENTS, OR NON-INFRINGEMENT OF THE PATENT OR OTHER RIGHTS OF ANY THIRD PARTY. 

5.05 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR
INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH 

  
 8 

 
DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 6.01, OR
DAMAGES AVAILABLE FOR A PARTY’S BREACH OF THE CONFIDENTIALITY OBLIGATIONS IN SECTION 8.11. 
 ARTICLE VI 

LIABILITY 
 6.01
Indemnification by Coherus. Coherus shall indemnify, defend and hold Genentech and its Affiliates and their respective directors, officers, employees and agents harmless from and against any and all liabilities, claims, demands, expenses
(including, without limitation, reasonable attorneys’ and professional fees and other costs of litigation), losses or causes of action (each, a “Liability”) arising out of or relating in any way to (i) the possession,
manufacture, use, sale or other disposition of Licensed Product hereunder, whether based on breach of warranty, negligence, product liability or otherwise, (ii) the exercise of any right granted to Coherus, its Affiliates or Sublicensees
pursuant to this Agreement, or (iii) any breach of this Agreement by Coherus, its Affiliates or Sublicensees, except to the extent, in each case, that such Liability is caused by the negligence or willful misconduct of Genentech, its directors,
officers, employees and/or agents as determined by a court of competent jurisdiction or arising out of or relating in any way to any material breach of Section 5.01 of this Agreement by Genentech; provided, however, that upon receiving
notice of any such Liability, Genentech shall promptly notify Coherus and permit Coherus to handle and control the defense (including litigation and settlement) of such Liability, at Coherus’ sole expense, and Genentech shall reasonably
cooperate with Coherus in the defense of such Liability, at Coherus’ sole expense. 
 ARTICLE VII 

TERM AND TERMINATION 
 7.01
Term. This Agreement will commence on the Effective Date and remain in full force and effect until the end of the Royalty Term (the “Term”), unless earlier terminated in accordance with this Article VII. 

7.02 Termination without Cause. Coherus has the right to terminate this Agreement for any reason upon a sixty (60) calendar day
prior written notice to Genentech. 
 7.03 Termination for Breach. Genentech shall have the right to terminate this Agreement and the
licenses granted hereunder upon written notice to Coherus for a material breach of this Agreement if Coherus has failed to cure such breach within thirty (30) calendar days following notice thereof. Coherus’ failure to pay royalties, and
provide reports, to Genentech pursuant to this Agreement when owed shall constitute a material breach. 
 7.04 Insolvency. Genentech
may terminate this Agreement if, at any time, Coherus shall file in any court pursuant to any statute of any individual state or country, a petition in bankruptcy, insolvency or for reorganization or for an agreement among creditors or for the

  
 9 

 
appointment of a receiver or trustee of Coherus or of its assets, or if Coherus proposes a written agreement of composition or extension of its debts, or if Coherus shall be served with an
involuntary petition against it filed in any insolvency proceeding, and such petition shall not be dismissed within sixty (60) days after the filing thereof, or if Coherus shall propose or be a party to any dissolution or liquidation, or if
Coherus shall make an assignment for the benefit of creditors. Any termination pursuant to this section shall be effective immediately upon notice of such termination. 

7.05 Effect of Termination. Termination of this Agreement in whole or in part for any reason shall not relieve Coherus of its
obligations to pay all fees and royalties that shall have accrued hereunder prior to the effective date of termination. Termination of this Agreement as to Coherus shall result in the termination of the licenses granted to Coherus and of all
sublicenses hereunder, except as set forth in Section 7.06 below. The provisions of Article I, Article IV, Article V, Article VI, Section 7.05 and Section 7.06, and Article VIII shall
survive termination of the Agreement for any reason. 
 7.06 Direct License to Sublicensee on Termination. A sublicense granted by
Coherus to a Sublicensee in accordance with this Agreement shall survive termination of this Agreement and shall be deemed to be a direct license from Genentech to such Sublicensee, provided that (i) such Sublicensee is then in full compliance
with all terms of this Agreement and the respective sublicense, (ii) such Sublicensee agrees in writing to assume all of the obligations of Coherus that are within the scope of the sublicense granted to such Sublicensee (i.e. subject to any
territorial or field limitations in the sublicense to such Sublicensee) under this Agreement and can reasonably show the capacity to comply with such obligations to the same extent as if such Sublicensee were an original party hereto, (iii) the
obligations of Genentech under such direct license shall not be greater than the obligations of Genentech under this Agreement, and (iv) the scope of such direct license shall not be broader than the rights sublicensed by Coherus to such
Sublicensee. 
 7.07 Challenge to Licensed Patents. The Parties acknowledge and agree that Genentech may terminate the Agreement at
Genentech’s sole and absolute discretion, in the event Coherus, its Affiliate or a Sublicensee challenges, or knowingly participates with or assists a Third Party to challenge the validity, enforceability, patentability and/or scope of any
claim within the Licensed Patents in a court or patent office or other governmental agency (for a Sublicensee only, this section shall apply to such challenge only with respect to a Licensed Product), [***]. In the event
of termination by Genentech pursuant to this section, any royalty or other payment owed to Genentech prior to such termination shall be non-refundable. 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  
 10 

 ARTICLE VIII 

MISCELLANEOUS PROVISIONS 
 8.01
Relationship of the Parties. Nothing in this Agreement is intended or shall be deemed to constitute or give rise to a partnership, agency, distributorship, employer-employee, joint venture, or fiduciary relationship between the Parties. No
Party shall incur any debts or make any commitments for the other. 
 8.02 Patent Prosecution, Maintenance and Enforcement. Genentech
shall be solely responsible, at its sole discretion and expense, for the prosecution, defense, and maintenance of Licensed Patents, and for enforcing Licensed Patents against actual or suspected Third Party infringers. 

8.03 Assignment. Neither Party shall assign any of its rights or obligations hereunder except: (a) as incident to the merger,
consolidation, reorganization or acquisition of stock or assets affecting substantially all of the assets or voting control of the assigning Party; (b) in the case of Coherus, to any corporation or other entity to which it may transfer all or
substantially all of its assets related to the Licensed Product; (c) to any Affiliate if the assigning Party remains liable and responsible for the performance and observance of all of the Affiliate’s duties and obligations hereunder; or
(d) with the prior written consent of the other Party (which consent shall not be unreasonably withheld). This Agreement shall be binding upon the successors and permitted assigns of the Parties, and the name of a Party appearing herein shall
be deemed to include the names of such Party’s successor’s and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in accordance with this section shall be void. 

8.04 Further Acts and Instruments. Upon request by either Party, the other Party agrees to execute, acknowledge and deliver such
further instruments, and to do all such other acts, as may be reasonably necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

8.05 Trade names and Trademarks. Except as otherwise provided herein, no right, express or implied, is granted to a Party by this
Agreement to use in any manner the name of the other Party or its Affiliates or any other trade name, trademark or logo of the other Party or its Affiliates. 

8.06 Entire Agreement. This Agreement and the Confidentiality Agreement dated [***] between the Parties constitute and contain
the entire understanding and agreement of the Parties and cancel and supersede any and all prior negotiations, correspondence, understandings and agreements, whether verbal or written, between the Parties respecting the subject matter hereof. No
waiver, modification or amendment of any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized representative of each of the Parties. 

8.07 Severability. In the event any one or more of the provisions of this Agreement should for any reason be held by any court or
authority having jurisdiction over this Agreement 
  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 11 

 
or either of the Parties to be invalid, illegal or unenforceable, such provision or provisions shall be validly reformed to as nearly as possible approximate the intent of the Parties and, if
such provision cannot be reformed, shall be divisible and deleted in such jurisdiction; elsewhere, this Agreement shall not be affected so long as the Parties are still able to realize the principal benefits bargained for in this Agreement. 

8.08 Waiver. The waiver by a Party of any breach of or default under any of the provisions of this Agreement or the failure of a Party
to enforce any of the provisions of this Agreement or to exercise any right hereunder shall not constitute or be construed as a waiver of any other breach or default or as a waiver of any such rights or provisions hereunder. 

8.09 Choice of Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of California without
regard to its conflict of laws provisions. This Agreement shall be construed as if drafted equally by the Parties, and in construing this Agreement no presumption shall operate in either Party’s favor as a result of the role of it or its
counsel in drafting or negotiating the terms or provisions hereof. 
 8.10 Notices. Any notice, request, consent, or other document
required or permitted to be given under this Agreement or otherwise relating to this Agreement shall be in writing and shall be deemed to have been sufficiently given if delivered in person, transmitted by facsimile (with a confirming copy sent by
overnight courier), or sent by overnight courier or registered mail to the Party to whom it is directed at its address shown below or such other address as such Party shall have last given by notice to the other Party. Any such notice, requests,
delivery, approval or consent shall be deemed received on the date of hand delivery or transmission by facsimile (provided that such date is a business day, otherwise it shall be deemed received on the next business day), one (1) business day
after dispatch by overnight courier, or five (5) business days after dispatch of the registered mail. 
 If to Coherus, addressed to:

 Coherus Inc. 
 201 Redwood
Shores Parkway, 
 Suite 200, 

Redwood City, CA 94065 
 Attn:
President and Chief Executive Officer 
 Facsimile: (866) 491-7350 

If to Genentech, addressed to: 

Genentech, Inc. 
 1 DNA Way 

South San Francisco, CA 94080 

Attn: Corporate Secretary 

Facsimile: (650) 467-9146 

8.11 Confidentiality. Neither Party shall disclose any of the terms of this Agreement (including, but not limited to, the financial
terms), and Genentech shall not disclose reports 

  
 12 

 
provided pursuant to Section 4.02 or notices provided pursuant to Section 2.02, to any Third Party, in each case without the prior written consent of the other Party;
provided, however, that each Party shall be free to disclose any of the terms of this Agreement (i) to the extent that a Party reasonably believes, upon advice of legal counsel, that it is required to do so by securities or other applicable
laws, regulations, or rules (including the regulations or rules of any relevant stock exchange), (ii) pursuant to a legal proceeding or order of a court or governmental agency, (iii) to actual or prospective sublicensees, (iv) in the
case of Genentech, to its Affiliates and to the City of Hope, (v) to its accountants, attorneys and other professional advisors, (vi) in the case of Coherus, to Affiliates and/or Designees or (vii) in connection with a financing,
merger, consolidation, acquisition or a permitted assignment of this Agreement, provided that in the case of any disclosure under (iii), (iv), (v), (vi) or (vii) above, the recipient(s) are obligated and do so undertake to keep such terms
of this Agreement confidential to the same extent as said Party, and provided that in the case of disclosure under (ii), the disclosing Party will use reasonable efforts to secure confidential treatment of such terms of this Agreement as are
required to be disclosed. 
 8.12 Publicity. Neither Party shall issue any press release or other publicity material or make any
public representation that refers to the terms, including, without limitation, the financial terms, of this Agreement without the prior written consent of the other Party, such consent not to be unreasonably withheld. 

8.13 Counterparts. This Agreement may be executed simultaneously in one or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. For purposes hereof, a facsimile copy, or email with attached pdf copy of this Agreement, including the signature pages hereto, will be deemed to be an original. 

[Signature page follows] 

  
 13 

 IN WITNESS WHEREOF, Genentech and Coherus have caused this Agreement to be executed by their duly
authorized representatives. 
  

			
	GENENTECH, INC.
		
	By:	 	 /s/ Steve Krognes

	Name: Steve Krognes
	Title: Chief Financial Officer
	
	COHERUS BIOSCIENCES, INC.
		
	By:	 	 /s/ Dennis M. Lanfear

	Name: Dennis M. Lanfear
	Title: President and Chief Executive Officer

  
 14Prepared by R.R. Donnelley Financial -- EX-10.5

 Exhibit 10.5 

CONFIDENTIAL 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 SELEXIS 

COMMERCIAL LICENSE AGREEMENT 

ENTERED INTO WITH 

BIOGENERICS, INC. 

 CONFIDENTIAL 

 

 This Commercial License Agreement (the “Agreement”) is made effective
on April 8, 2011 (the “Effective Date”), by and between SELEXIS SA, 18 chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland SA (“Selexis”) and BIOGENERICS, INC. 555 Bryant Street, Ste 266,
Palo Alto, CA 94301 (“COMPANY”). 
 BACKGROUND 

Whereas, COMPANY is a biopharmaceutical Company engaged in the research, development, manufacturing and sale of
biopharmaceutical products and 
 Whereas, Selexis is a biotechnology Company engaged in the development and sale of recombinant cell
lines based on proprietary technology (“Selexis Technology”, as defined further below); and 
 Whereas, Selexis is the
owner of certain proprietary and confidential information and know-how (“Selexis Know-How”, as defined further below), and intellectual property (“Selexis Patent Rights”, as defined further below); and 

Whereas, Pursuant to a Services Agreement dated April 8, 2011 Selexis has developed certain recombinant cell lines for
COMPANY based on Selexis Technology and COMPANY has evaluated such cell lines; and 
 Whereas, Selexis is
willing to grant COMPANY, and COMPANY is willing to receive from Selexis, Selexis Know-How and Selexis Patent Rights and licenses thereto related to the Selexis Technology, on the terms and conditions set forth herein. 

AGREEMENT 
 Now,
therefore, the Parties, intending to be legally bound hereby, do hereby agree as follows: 
  

	1.	DEFINITIONS 

 The following capitalized terms, whether used in the singular or the
plural, shall have the following meanings as used in this Agreement, unless otherwise specifically indicated: 
 1.1.
“Affiliate” shall mean any Person that, at the date of this Agreement, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with the Party specified. For the purposes of
this definition, “control.’ shall mean the possession, direct or indirect, of the power to cause the direction of the management and policies of a Person, whether through ownership of fifty percent (50%) or more of the voting
securities of such Person, by contract or otherwise. A Person shall only be considered an Affiliate for so long as such control exists. 

1.2. “Agreement” shall mean as defined on Page 2, 1st paragraph. 

  
 1 

 CONFIDENTIAL 

 

 1.3. “Biosimilar of [***]” shall mean a biological product that is
demonstrated to be clinically or biophysically “highly similar” (biosimilar) to, or “interchangeable” with, the FDA-licensed biological product [***]. 

1.4. ‘‘Calendar Quarter” shall mean for each Calendar Year, each of the three month periods ending
March 31, June 30, September 30 and December 31. 
 1.5. “Calendar Year” shall mean the
period commencing on January 1 and ending twelve (12) consecutive calendar months later on December 31. 
 1.6. “Cell
Line” shall mean a mammalian cell line that is developed using the Selexis Technology. 
 1.7. “Clinical Trials”
shall mean human studies designed to measure the safety and/or efficacy of the Product. Clinical Studies include Phase 1 Clinical Trials, Phase II Clinical Trials, and Phase Ill Clinical Trials. 

1.8. “Collaboration Partner” shall mean a Third Party with which COMPANY collaborates on the development of the
production process and/or commercialization of a Product or to which COMPANY has granted a license for the development of the production process and/or commercialization of a Product. 

1.9. “Combination Product” shall mean a Product that contains (a) a Biosimilar of [***] and (b) one
(1) or more devices, components or therapeutically active pharmaceutical ingredients other than a Biosimilar of [***]. 
 1.10.
“Combination Product Adjustment” shall mean the following: Net Sales for such combination product will be adjusted by multiplying actual Net Sales of such combination product by the fraction N(A + B) where A is the weighted (by
sales volume) average invoice price of the Product, if sold separately, and B is the weighted (by sales volume) average invoice price of any other active ingredient, device or component in the combination, if sold separately. If, on a
country-by-country basis, the other active ingredient, device or component in the combination is not sold separately, Net Sales shall be calculated by multiplying actual Net Sales of such combination product in such country by the fraction NC where
A is the invoice price of the Product, if sold separately, in such country and C is the invoice price of the combination product in such country. If, on a country-by-country basis, neither the Product, nor the other active ingredient, device or
component of the combination product, is sold separately, Net Sales shall be [***]. 
 1.11. “Commercial License”
shall mean as defined in Section 2.1. 
 1.12. “Commercial License Option” shall mean as defined in Section 2.1.

 1.13. “Confidential Information” shall mean and include but not be limited to any technical and business information
pertaining to materials and production techniques, products, processes and services, including without limitation relating to physical working models and samples of the products, research, development, patentable and unpatentable inventions,
manufacturing, purchasing and product development plans, forecasts, strategies and information, 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  
 2 

 CONFIDENTIAL 

 

 
engineering, marketing, merchandising, selling, customer lists, customer prospects, software codes, algorithms, names and expertise of employees and consultants, blueprints, technical
information, trade secrets or know how or other related proprietary business information and data, in any case whether such information is provided in tangible or intangible form, written, oral, graphic, pictorial or recorded form or stored on
computer discs, hard drives, magnetic tape or digital or any other electronic medium if it is labelled or declared “Confidential” or if a party may reasonably assume that the information received must be treated confidential. Confidential
Information shall also include any information or documents the Recipient received in confidence from a third party that are subject to similar covenants as those contained in this Agreement. 

1.14. “Contractor” shall mean a Third Party contractor who: (i) develops the production process for Products or
(ii) manufactures and supplies Products by using such production process. 
 1.15. “Default” shall mean as defined in
Section 7.2. 
 1.16. “Defaulting Party” shall mean as defined in Section 7.2. 

1.17. “Effective Date” shall have the meaning as given on Page 2, 1st paragraph. 

1.18. “[***]” shall mean the biologically active protein with the identical protein sequence to commercially available [***] which
[***]. 
 1.19. “FDA” shall mean the United States Food and Drug Administration, or any successor agency. 

1.20. “First Commercial Sale” shall mean, with respect to any Product in any country, the first sale of such Product for
value and for end-use or consumption by the general public in such country after Regulatory Approval as well as Pricing and Reimbursement Approval for such Product has been obtained in such country. For the avoidance of doubt, sales prior to receipt
of all Regulatory Approvals and Pricing and Reimbursement Approvals necessary to commence regular commercial sales, such as so-called “treatment IND sales”, “named patient sales” and “compassionate use sales”, and sales
for research or other noncommercial purposes shall not be construed as a First Commercial Sale. 
 1.21. “Force Majeure”
shall mean any occurrence beyond the reasonable control of a Party that prevents or substantially interferes with the performance by the Party of any of its obligations hereunder. 

1.22. “COMPANY” shall mean as defined on Page 2, 1st paragraph. 

1.23. “IND” shall mean an Investigational New Drug Application for the Product filed with the FDA pursuant to 21 C.F.R. Part
312, or any comparable filing made with a Regulatory Authority in another country (including the submission to a competent authority of a request for an authorisation concerning a clinical trial, as envisaged in Article 9. paragraph 2, of European
Directive 2001/20/EC). 
  
 [***] Certain information in this document has been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 3 

 CONFIDENTIAL 

 

 1.24. “Insolvent Party” shall mean as defined in Section 7.3. 

1.25. “Invention” shall mean any invention, idea, innovation, enhancement, improvement or feature, whether or not patentable
or registrable, together with any intellectual property rights relating thereto (including without limitation Patent Rights and rights in confidentiality and proprietary information). 

1.26. “Know-How” shall mean information in whatever form, including in any electronic, tangible or intangible medium, and
includes information and materials relating to Inventions and other know-how, trade secrets, data (including amongst other things all data from pre-clinical and clinical studies and other studies intended for regulatory submission), results,
formulae, DNA and amino acid sequence information and developments. 
 1.27. “Licensed Field of Use” shall mean the
treatment, prevention, diagnosis and palliation of all disease. 
 1.28. “Losses” shall mean as defined in
Section 6.1. 
 1.29. “Net Sales” shall mean the amount collected by COMPANY, its Affiliates and/or its
sublicensees on account of sales of Product to Third Parties in the Territory, less the following deductions: 
 1.29.1. sales and excise
taxes arid duties paid or allowed by the selling party and any other governmental charges imposed upon the production, importation, use or sale of the Products; 

1.29.2. bona fide trade, quantity and cash discounts allowed on Products; 

1.29.3. bona fide rebates; 

1.29.4. allowances or credits to customers on account of rejection or return of Product or on account of retroactive price reductions
affecting the Product; and 
 1.29.5. freight and insurance costs, if they are included in the selling price for the product invoiced to
Third Parties or if they are billed separately on an invoice, provided always that such deduction shall not be greater than the balance between the selling price actually invoiced to the Third Party and the standard selling price which would have
been charged to such Third Party for such Product exclusive of freight and insurance in the respective country or in a comparable country. 

In the event that Products are sold in any country in the form of a Combination Product, the Net Sales for any such Combination Product shall
be computed pursuant to the Combination Product Adjustment in such country. 
 In the event that Products are sold to a Third-Party
distributor for purposes of resale by the distributor, the distributor shall be considered a Third Party, and not a sublicensee, for purposes of determination of Net Sales, regardless of whether the distributor has entered into any sublicense with
COMPANY. 

  
 4 

 CONFIDENTIAL 

 

 Sales of a Product between COMPANY and its Affiliates or sublicensees for
resale shall be excluded from the computation of Net Sales, but the subsequent resale of such Product to a Third Party shall be included within the computation of Net Sales. Any free-of-charge disposal or use of a Product for development, regulatory
or marketing purposes, such as clinical trials, compassionate use or indigent patient programs, shall not be deemed a sale or disposition for purposes of calculating Net Sales. 

1.30. “Non-Defaulting Party” shall have the meaning as given in Section 7.2. 

1.31. “Notice of Default” shall have the meaning as given in Section 7.2. 

1.32. “Party” shall mean Selexis or COMPANY, as the case may be; and “Parties” shall mean
Selexis and COMPANY, collectively. 
 1.33. “Patent Rights” shall mean any and all of the following:
(i) patent applications (including provisional patent applications) and patents (including the inventor’s certificates); (ii) any substitution, extension (including patent term extensions and supplementary protection certificate),
registration, confirmation, reissue, continuation, divisional, continuation-in-part, re-examination, renewal, patent of addition or the like thereof or thereto; (iii) any foreign counterparts of any of the foregoing; and (iv) any utility
model applications and utility models (whether or not corresponding to any of the foregoing). 
 1.34. “Person” shall mean
an individual, a partnership, a joint venture, a corporation, a limited liability Company, a trust, an estate, an unincorporated organization, or any other entity, or a government or any department or agency thereof, whether acting in an individual,
fiduciary or other capacity. 
 1.35. “Phase I Clinical Trial” shall mean a clinical trial conducted in humans which is
principally intended to obtain data on the safety, tolerability, pharmacokinetic or pharmacodynamic properties of a product. Phase I shall be deemed to have commenced when the first patient in the study has been treated. Phase I shall be deemed to
have completed when the last patient has completed his or her treatment being investigated by that clinical trial as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed for the
primary endpoint. 
 1.36. ‘‘Phase II Clinical Trial” shall mean a clinical trial conducted in humans in which the
primary objective is a preliminary determination of therapeutic efficiency and/or to find an optimal dose range in patients with the disease target being studied. Phase II shall be deemed to have commenced when the first patient in the study has
been treated. Phase II shall be deemed to have completed when the last patient has completed his or her treatment being investigated by that clinical trial as described in its protocol, the database is locked, and data from all patients, according
to protocol, has been analyzed for the primary endpoint. 
 1.37. “Phase III Clinical Trial” shall mean a clinical trial
conducted in humans in which the primary objective is a determination of therapeutic efficiency in patients with the disease target being studied, Phase Ill shall be deemed to have commenced when the first patient in the study has been treated,
Phase III shall be deemed to have completed when the last patient has 

  
 5 

 CONFIDENTIAL 

 

 
completed his or her treatment being investigated by that clinical trial as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed
for the primary endpoint. 
 1.38. ‘‘Price and Reimbursement Approval’’ shall mean any approvals, licences,
registrations or authorisations of any supranational, national, regional, state or local Regulatory Authority or other regulatory agency, department, bureau or governmental entity, necessary to determine or set the pricing of a Product, and/or its
reimbursement level by the relevant health authorities, providers or other funding institutions, at supranational, national, regional, state or local level. 

1.39. “Product” shall mean any pharmaceutical preparation in final form containing a Biosimilar of [***] as one of its
active ingredients, such Biosimilar of [***] having been manufactured using a Cell Line. 
 1.40. “Regulatory
Approval” shall mean any approvals, licences, registrations or authorisations of any supranational, national, regional, state or local Regulatory Authority or other regulatory agency, department, bureau or governmental entity, necessary for
the manufacture, marketing or sale of the Product or conduct of clinical trials in a regulatory jurisdiction, excluding Price and Reimbursement Approval. 

1.41. “Regulatory Authority” shall mean (i) the FDA or (ii) any and all governmental or supranational agencies,
ministries, authorities or other bodies with similar regulatory authority with respect to approval or registration of pharmaceutical or biologic products in any other jurisdiction anywhere in the world. 

1.42. “Royalty Term” means with respect to each Product sold in a particular country, the period beginning on the date of
First Commercial Sale in such country and terminating on the expiration of the last-to-expire or lapse of any Valid Claims covering the Product in such country. 

1.43. “Selexis” shall have the meaning as given on Page 2, 1st paragraph. 

1.44. “Selexis Know-How” shall mean Selexis’ Confidential Information and Know-How relating to the construction and
development of recombinant cell lines for the manufacture of biopharmaceutical products and existing as of the Effective Date or obtained thereafter during the term of this Agreement. 

1.45. “Selexis Materials” shall mean the materials provided by Selexis to COMPANY under this Agreement and all
modifications and improvements thereof made by Selexis during the term hereof. 
 1.46. “Selexis Patent Rights” shall mean
Patent Rights that: (i) are owned or controlled by Selexis, (ii) which are necessary or useful for the use of Selexis Materials or the construction and development of Cell Lines, or the use, manufacture and purification of a Biosimilar of
[***] and/or the Product, and (iii) are existing as of the Effective Date or obtained 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  
 6 

 CONFIDENTIAL 

 

 
thereafter during the term of this Agreement. Without limiting the definition set forth in this Section 1.46 the Selexis Patent Rights as of the Effective Date are listed in Exhibit 1
hereto. 
 1.47. “Selexis Technology” shall mean the Selexis Patent Rights, Selexis Know-How and Selexis Materials. 

1.48. “Taxes” shall mean all excises, taxes and duties with the exception of VAT. 

1.49. “Term” shall mean as defined in Section 7.1. 

1.50. “Territory” shall mean the entire world. 

1.51. “Third Party” shall mean a Person other than Selexis, COMPANY or an Affiliate of Selexis or COMPANY. 

1.52. “Valid Claim” shall mean any issued or granted claim of the Selexis Patent Rights that has not been revoked or held
unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, that is unappealable or remains unappealed at the end of the time allowed for appeal, or that has not been disclaimed, denied or admitted to be
invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. 
 1.53. ‘VAT’ shall mean value added
tax and any other similar turnover, sales or purchase, tax or duty levied by any other jurisdiction whether central, regional or local. 
  

	2.	COMMERCIAL LICENSES 

 2.1. Commercial Licenses. Selexis hereby grants to
COMPANY and its Affiliates a non-exclusive license (“Commercial License”) in the Territory, with the right to sublicense as per clause 2.2 hereafter, under the Selexis Technology, subject to the terms and conditions of the
Agreement, to use Cell Lines for the manufacture of Products in the Licensed Field of Use and to make, have made, use, offer for sale, sell, import and otherwise exploit Products, including, without limitation, the use of Products in Clinical
Trials. 
 2.2. Sublicenses. COMPANY may grant sublicenses under the foregoing Commercial License and/or transfer the Cell
Lines and Selexis Know-How to a Third Party. For the avoidance of doubt, COMPANY shall not transfer Cell Lines to a Third Party for any purpose other than to make, have made, use, offer for sale, sell, import and otherwise exploit Products.
Any agreement granting such sublicence shall be consistent with the terms, conditions and limitations of this Agreement. In any event, COMPANY is fully liable and responsible for any breach of any of its obligations hereunder committed by an
Affiliate, a Collaboration Partner or Contractor, a consultant or agent to whom the Cell Line and the Selexis Technology or parts thereof are made available under any such sublicense. Selexis agrees that, to the extent (i) provided for in each
sublicense granted under this Agreement and (ii) such sublicense does not impose any obligations on Selexis in excess of those imposed on Selexis herein, all sublicenses granted with respect to the rights granted under this Agreement shall
survive termination of this Agreement and will automatically be assigned to Selexis upon such termination, in order to provide for the applicable sublicensee’s continued enjoyment of its rights thereunder. 

  
 7 

 CONFIDENTIAL 

 

 2.3. Transfer of Selexis Materials. COMPANY shall [***]. If
COMPANY makes any such transfer it shall notify Selexis within 30 days of any such transfer and report the name and address of any Transferees together with confirmation that the Transferee has agreed to adhere to the obligations of
confidentiality set out in this Agreement. 
  

	3.	CONSIDERATION 

 3.1. Payments. 

3.1.1. Commercial License Exercise Payment. Upon the execution of this Agreement, COMPANY shall pay Selexis the sum of
[***]. 
 3.1.2. Commercial License Milestone Payments. As consideration for the rights and licenses granted by Selexis to
COMPANY under this Agreement, COMPANY shall make the following milestone payments to Selexis with respect to the first occurrence of such milestone events: 
  

											
		  	(a)	  	upon	  	[***]:	 	[***];	 	
						
		  	(b)	  	upon	  	[***]:	 	[***];	 	
						
		  	(c)	  	upon	  	[***]:	 	[***];	 	
						
		  	(d)	  	upon	  	[***]:	 	[***].	 	

 The payments set forth above in this Section 3.1.2 shall be payable only once for each milestone event,
upon the first occurrence of such milestone event, regardless of the number of times each event occurs. 
 3.1.3. Commercial License
Royalty Payments. In addition to the milestone payments, during the Royalty Term COMPANY shall pay Selexis on a Product-by-Product and country-by-country basis a royalty of [***] of Net Sales of all Products sold worldwide. In the
case where royalties are due in respect of the sale of Product directly by COMPANY such royalties shall be paid for each Calendar Quarter within forty-five (45) days of the end of that Calendar Quarter. Where royalties are due in respect
of the sale of Products by a sub-licensee of COMPANY payment shall be made within ninety (90) days of the end of that Calendar Quarter. For the avoidance of doubt no royalty payments shall be due in any country after the Royalty Term has
expired in such country Where royalties are no longer due in accordance with the foregoing in respect of any Product in any country, the Commercial Licences granted to COMPANY under this Agreement shall become perpetual, irrevocable, 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 8 

 CONFIDENTIAL 

 

 
fully paid up and royalty free in respect of such Product in such country and notwithstanding Section 2.3, COMPANY shall have the right to transfer the Selexis Materials to any Third
Party in connection with the manufacture, use and sell of such Product in such country. 
 3.2. Mechanism of Payment. The payments
due to Selexis under this Agreement shall be made by wire transfer or electronic fund transfer (at COMPANY’s discretion) to the credit and account of Selexis as follows: 

 

					
	Bank Name:	  	[***]	  	
		  	[***]	  	
		  	[***]	  	
			
	Account:	  	[***]	  	
		  	[***]	  	
		  	[***]	  	
		  	[***]	  	
			
	To:	  	Selexis S.A.	  	
		  	18, chemin des Aulx	  	
		  	1228 Plan-les-Ouates	  	
		  	Geneva, Switzerland	  	

 3.3. Payment Terms. Save as provided in Section 3.1.3, COMPANY shall make payments due to
Selexis under this Agreement at the latest [***] after receipt of invoice except where such fees are due from a COMPANY licensee, in which case COMPANY shall have [***] after receipt of invoice to make such payments. All
such fees and payments are exclusive of any applicable VAT, other taxes, duties and excises (collectively, “Taxes”). 

3.4. Records. COMPANY and its Affiliates shall keep (and COMPANY shall use its best endeavours to procure that its
sub-licensees shall keep and make available to COMPANY) true accounts of Net Sales of Products and COMPANY shall deliver to Selexis at the same time as the payments due under Section 3.1.3. a written account, including quantities
of Net Sales of each such Product, broken down on a country-by-country basis in respect of those payments. Upon not less than sixty (60) days’ prior written notice, Selexis is entitled to have such accounts audited by an independent expert
of its choice for a period of [***] after receiving any such written account, solely to verify the accuracy of payments reported and paid hereunder. Such audits may be made no more than once each calendar year and during normal business
hours, with reasonable efforts to minimize disruption of COMPANY’S normal business activities. Such independent expert shall be bound by confidentiality terms at least as restrictive as the terms of Clause 10 of this Agreement and shall
be authorized to disclose to Selexis only the amount and accuracy of payments reported and actually paid or otherwise payable under this Agreement. COMPANY shall provide access to all information reasonably requested by such expert. The cost
of any audit shall be borne by Selexis unless the audit shows that COMPANY underpaid Selexis by more than 2% of the amounts due in which case the cost of the audit shall be borne by COMPANY. 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 9 

 CONFIDENTIAL 

 

 3.5. Taxes. [***] will pay [***] taxes levied on account of any payments
made to Selexis under this Agreement (other than taxes on income, gains or profits levied against [***]). If any taxes are required to be withheld by Company from any payment made to Selexis under this Agreement, Company will (a) deduct
such taxes from the payment made to Selexis, (b) timely pay the taxes to the proper taxing authority, and (c) send proof of payment to Selexis and certify its receipt by the taxing authority within thirty (30) days following such
payment. 
 3.5.1. Single Royalty. Nothing shall oblige COMPANY or its sublicensees to pay or cause to be paid to Selexis more
than one royalty on any unit of Product, irrespective of how many Selexis Patent Rights may cover such Product. 
  

	4.	INTELLECTUAL PROPERTY 

 4.1. Ownership. Each Party shall retain the entire right
and title in and to its Inventions and Know-How which exists on the Effective Date of this Agreement or which is thereafter developed independently of the performance of this Agreement. 

4.2. In the event Selexis possesses, acquires, creates or is licensed any improvements to the Selexis Technology, subject to any bona fide
obligations owed by Selexis to third parties (in respect of which Selexis has notified COMPANY), such improvements shall automatically be included in the Selexis Patent Rights and/or the Selexis Know-how and thereby disclosed and licensed at
no extra cost to COMPANY in accordance with this Agreement. 
 4.3. Third Party Patent Rights. 

4.3.1. Selexis covenants that if Selexis becomes aware or reasonably determines that the practice of the Selexis Technology and/or use of the
Cell Lines in order to make, have made, use, sell, offer for sale or import any Product in the Field in the Territory would, or would allegedly infringe or misappropriate any Third Party’ Patent Rights, Know-How or other intellectual property
rights. it shall notify COMPANY of the same within five (5) days (the “Infringement Notice”). Selexis shall use its best efforts to promptly resolve such infringement at Selexis’ cost to ensure that COMPANY
may exercise its rights under this Agreement without infringing or misappropriating such Patent Rights, Know-How or other intellectual property rights , including using its best efforts to obtain a license from the Third Party owner of such Patent
Rights, Know-How or other intellectual property which entitles Selexis to continue to grant the rights to COMPANY set forth herein. Should such efforts not be successful, Selexis shall inform COMPANY in writing. Selexis shall be
responsible for payment of any and all fees, milestones, royalties or other payments owed to any Third Party for any Patent Rights or Know-How or other intellectual property rights licensed or acquired by it after the Effective Date, which are
necessary or useful for COMPANY to make, have made, use, sell, offer for sale or import any Product in the Field in the Territory without infringing or misappropriating a Third Party’s Patent Rights, Know-How or other intellectual
property right. 
 4.4.Enforcement of Selexis Patent Rights. If during the Term, either Party becomes aware of any infringement or
potential infringement of the Selexis Technology it shall promptly notify the other Party in writing and the Parties shall consult with each other to decide the best 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  
 10 

 CONFIDENTIAL 

 

 
way to respond to such infringement or misuse. Selexis covenants that if Selexis becomes aware of an infringement of the Selexis Patent Rights by Third Parties in the Licensed Field of Use,
Selexis shall use its reasonable commercial efforts to prevent or enjoin such infringement. 
 4.5. COMPANY Intellectual
Property. COMPANY shall retain all right, title and interest in (and the unrestricted right to use) any and all information, data, results, Know-How, products and the like, whether patentable or not, arising out of the conduct of the
licenses granted hereunder and all intellectual property appurtenant thereto, including without limitation the Product composition or sequence and any related intellectual property. COMPANY shall have the unrestricted right to publish or
otherwise disclose the results and data obtained by the practice of the Selexis Technology provided such disclosure does not include the Confidential Information of Selexis. The name of Selexis shall be given proper recognition in such
publication(s) as scientifically appropriate. 
 4.6. Further Assurance. Each Party agrees to execute and do all things at the cost
of the other Party (it not specifically agreed otherwise) as the other Party may reasonably require to give that other Party the full benefit of the provisions of this Section 4. 

 

	5.	REPRESENTATIONS, WARRANTIES, AND COVENANTS 

 5.1. Corporate Power. Each Party
hereby represents and warrants that such Party is duly organized and validly existing under the laws of the state (or country or other jurisdiction, as the context requires) of its incorporation and has full corporate power and authority to enter
into this Agreement and to carry out the provisions hereof. 
 5.2. Due Authorization. Each Party hereby represents and warrants that
such Party is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder and the person executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate actions. 

5.3. Binding Agreement. Each Party hereby represents and warrants that this Agreement is a legal and valid obligation binding upon it
and is enforceable in accordance with its terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by
general equitable principles and public policy. 
 5.4. No Conflicts. Each Party hereby represents and warrants that the execution,
delivery and performance of this Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a Party or by which it may be bound, nor violate any law or regulation of any court,
governmental body or administrative or other agency having authority over it. 
 5.5. Additional Warranties by Selexis. Selexis
hereby warrants, represents and covenants to COMPANY that, to the best of its knowledge; 

  
 11 

 CONFIDENTIAL 

 

 5.5.1. As of the Effective Date, there are no Third Party intellectual property rights that
may be asserted against COMPANY claiming that the use by COMPANY of the Selexis Technology under this Agreement constitutes an infringement thereof; 

5.5.2. As of the Effective Date, there is no pending litigation which alleges that the use of Selexis Technology has infringed or
misappropriated any of the intellectual property rights of any Third Party, and Selexis has not received any written claim that the use of Selexis Technology infringes on any intellectual property rights of a Third Party or a request or demand from
any Third Party for the licensing of any intellectual property rights of such party in connection with the practice of the Selexis Technology; 

5.5.3. Selexis is the owner of or controls the Selexis Technology, and has the right to grant COMPANY the rights and licenses granted
COMPANY under this Agreement, and will not, knowingly during the Term, grant any rights to any Third Party that would adversely affect COMPANY ‘s rights or licenses granted under this Agreement. 

5.5.4. The Selexis Technology is free and clear of any encumbrance, lien, mortgage, charge, restriction or liability of any kind whatsoever,
whether equitable or legal, that would conflict with or impair the rights granted to COMPANY under this Agreement; 
 5.5.5. As of
the Effective Date, none of the Selexis Patent Rights are involved in any interference or opposition proceeding, and Selexis has not received any request, demand or notice from any Third Party threatening or disclosing such a proceeding with respect
to any of the Selexis Patent Rights; and 
 5.5.6. As of the Effective Date, Selexis has not received any statement or assertion that
(i) any claim in any of the Selexis Patent Rights is, or may be or become rendered, invalid or unenforceable, (ii) any Third Party is aware of any basis as to the Future potential invalidity or unenforceability of any claim of any of the
Selexis Patent Rights, or (iii) the Selexis Patent Rights do not list all required inventors. 
 5.5.7. Any replacement Selexis
Materials shall satisfy the characteristics set forth in the Selexis Report and shall be free of mycoplasma or other pathogenic contamination. 

5.6. Additional Warranties by COMPANY. COMPANY hereby warrants, represents and covenants to Selexis that, to the best of
its knowledge: 
 5.6.1. As of the Effective Date, there is no pending litigation which alleges that the use of the DNA sequence
replicated by the Cell Line has infringed or misappropriated any of the intellectual property rights of any Third Party, and COMPANY has not received any claim that the use thereof infringes on any intellectual property rights of a Third
Party or a request or demand from any Third Party for the licensing of any intellectual property rights of such party in connection with the use of the DNA sequence replicated by the Cell Line; 

5.7. Notification. Selexis shall notify COMPANY promptly during the Term, if: 

  
 12 

 CONFIDENTIAL 

 

 5.7.1. Selexis Patent Rights become involved in any interference or opposition proceeding, or
Selexis receives any request, demand or notice from any Third Party threatening or disclosing such a proceeding with respect to any of the Selexis Patent Rights; or 

5.7.2. Selexis receives any written statement or assertion that (i) any claim in any of the Selexis Patent Rights is, or may be or become
rendered, invalid or unenforceable, (ii) any Third Party is aware of any basis as to the future potential invalidity or unenforceability of any claim of any of the Selexis Patent Rights, or (iii) the Selexis Patent Rights do not list all
required inventors. 
 5.8. Disclaimer of Warranties by Selexis. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, SELEXIS DOES NOT
MAKE ANY REPRESENTATION OR WARRANTY TO COMPANY OF ANY NATURE, EXPRESS OR IMPLIED, THAT THE SELEXIS TECHNOLOGY WILL BE USEFUL FOR, OR ACHIEVE ANY PARTICULAR RESULTS AS A RESULT OF ANY USE BY COMPANY OF THE SELEXIS TECHNOLOGY PURSUANT TO
ANY LICENSE GRANTED TO COMPANY UNDER THIS AGREEMENT. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, SELEXIS SPECIFICALLY DISCLAIMS ANY WARRANTY OF NONINFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE. 

 

	6.	INDEMNIFICATION; LIMITATION OF LIABILITY 

 6.1. Indemnification by Selexis. During
the Term and thereafter, Selexis hereby agrees to save, defend and hold COMPANY, its Affiliates, and their respective officers, directors, employees, consultants and agents harmless from and against any and all liability, damage, loss or
expense (collectively, “Losses”) claimed by a Third Party resulting from (i) any breach of Selexis’ representations, warranties, and covenants set forth in this Agreement or (ii) the practice of licensed rights by
COMPANY in accordance with this Agreement, except to the extent that such Losses result from the gross negligence or intentional misconduct of COMPANY, its Affiliates, and their respective officers, directors, employees, consultants
and agents. In the event COMPANY seeks indemnification under this Section 6.1, COMPANY shall inform Selexis of a claim as soon as reasonably practicable after it receives notice of the claim, shall permit Selexis to assume
direction and control of the defense of the claim (including the right to settle the claim solely for monetary consideration), and shall cooperate as requested (at Selexis’ expense) in the defense of the claim but provided always that Selexis
may not settle any such claim or otherwise consent to an adverse judgment or order in any relevant action or other proceeding or make any admission as to liability or fault without the express written permission of COMPANY. 

6.2. Indemnification by COMPANY. During the Term and thereafter, COMPANY hereby agrees to save, defend and hold Selexis
and its officers, directors, employees, consultants and agents harmless from and against any and all Losses claimed by a Third Party (i) that the [***] or (ii) resulting from personal injury or damage to property caused by any
Products (including breach of the warranty pursuant to clause 5.6), except to the extent that COMPANY is indemnified by Selexis in respect of those Losses pursuant to Section 6.1 or that such Losses result from the gross negligence or
intentional misconduct of Selexis its Affiliates, 
  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 13 

 CONFIDENTIAL 

 

 
and their respective officers, directors, employees, consultants and agents. In the event Selexis seeks indemnification under this Section 6.2, Selexis shall inform COMPANY of a claim as
soon as reasonably practicable after it receives notice of the claim, shall permit COMPANY to assume direction and control of the defense of the claim (including the right to settle the claim solely for monetary consideration), and shall cooperate
as requested (at COMPANY’s expense) in the defense of the claim. 
 6.3. Insurance. COMPANY shall maintain product
liability insurance (or self-insure) in an amount consistent with industry standards; with respect to COMPANY, such insurance being in place by the time human clinical trials are initiated and maintained while clinical trials are underway or
Product is offered for sale. COMPANY shall name Selexis as an additional insured with respect to such insurance. Company shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to Selexis upon
request. 
 6.4. EXCEPT FOR LIABILITY FOR BREACH OF SECTION 8, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL,
INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER; provided however, that this Section 6.4 shall not be construed to limit either Party’s indemnification obligations under this
Section 6. 
 6.5. Limitation of Liability. Excluding breaches of Section 8, Selexis’ liability under Section 6,1
will in no event exceed [***] the aggregate amount paid to Selexis under this Agreement, and Selexis’ liability otherwise under this Agreement. whether in contract or tort or otherwise, will not exceed [***] the aggregate amount paid to Selexis
under this Agreement. 
  

	7.	TERM AND TERMINATION 

 7.1. Term. This Agreement shall enter into effect on the
Effective Date. Unless earlier terminated pursuant to Sections 7.2, 7.3 or 7.4 of this Agreement shall remain in full force and effect on a country-by-country and Product-by-Product basis until the expiration of the Royalty Term with respect to such
Product (such period, the “Term”). Upon expiration of the Term on a country-by-country and Product-by-Product basis, the Commercial Licences granted to COMPANY under this Agreement shall become perpetual, irrevocable, fully paid up
and royalty free in respect of such Product and country, and this provision shall survive expiration and termination of this Agreement. 

7.2. Termination for Default. In addition to any other remedies which may be available at law or equity, in the event of any material
breach of this Agreement by a Party (“Default”), the Party not in default (“Non-Defaulting Party”) shall have the right to give the other Party (“Defaulting Party”) written notice thereof
(“Notice of Default’’), which notice must state the nature of the Default in reasonable detail and request that the Defaulting Party cure such Default within [***] days. If such Default is not cured within the period set
forth herein after receipt of a Notice of Default by the Defaulting Party or if such Default is not capable of being cured, then the Non-Defaulting Party, at its option, may terminate this Agreement by written notice effective upon receipt. 

 
 [***] Certain information in this document has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 14 

 CONFIDENTIAL 

 

 7.3. Termination for Bankruptcy. In the event that a Party files for protection under
bankruptcy laws, files a petition under any bankruptcy or insolvency act or has such a petition filed against it which is not discharged in [***] days thereof , or makes any arrangement with its creditors or has a receiver or administrator
appointed to the whole or any part of its assets or if an order shall be made or a resolution passed for its winding up unless such order or resolution is part of a scheme for its amalgamation or reconstruction (“Insolvent Party”), the
other Party shall have the right to serve immediate notice of termination of this Agreement, effective upon receipt. 
 7.4. Termination
by COMPANY. COMPANY may terminate this Agreement at any time by giving sixty (60) days written notice to Selexis. 

7.5. Effects of Expiration or Termination. 

7.5.1. Termination of Licenses. In the event of a termination of this Agreement by COMPANY pursuant to Section 7.2, 7.3 or
7.4 or by Selexis pursuant to Sections 7.2 or 7.3, the rights and licenses granted under this Agreement shall terminate other than those licenses which have become perpetual as described in Sections 3.1.3 and 7.1. 

7.5.2. Selexis Confidential Information. Upon termination of this Agreement under Section 7.2 or 7.3 wherein COMPANY is the
Insolvent Party, or Section 7.4, COMPANY shall dispose of all tangible embodiments, including Selexis Materials, and render inaccessible or useless all electronic embodiments, of Selexis Confidential Information provided to
COMPANY by Selexis hereunder, except that (i) COMPANY may retain one (1) copy thereof for legal archival purposes, (ii) Company may retain any such Selexis Confidential Information to the extent necessary to exercise
rights under licenses that have become perpetual as described in Sections 3.1.3 and 7.1 and (iii) sublicensees possessing sublicenses that survive such termination may possess such Selexis Confidential Information. 

7.5.3. COMPANY Confidential Information. Upon any expiration or termination of this Agreement, Selexis shall dispose of all
tangible embodiments, and render inaccessible or useless all electronic embodiments, of COMPANY Confidential Information provided to Selexis by COMPANY hereunder, except that Selexis may retain one (1) copy thereof for legal
archival purposes. 
 7.5.4. Accrued Obligations. Expiration or termination of this Agreement shall not relieve the Parties of any
obligation or liability accruing prior to such expiration or termination and all ancillary provisions necessary for the implementation of this Section 7.5.5 shall survive termination. 

7.5.5. Survival. Sections 4, 6, 7.1, 7.5, 8, 9, and the final sentence of Section 3.1.3 shall survive termination or expiration of
this Agreement. 
 7.5.6. Wind Down. COMPANY and its Affiliates may continue, to the extent that COMPANY and its
Affiliates continue to have an inventory of Products, to fulfill orders received from customers for Products until up to twelve (12) months after the effective date of termination For the Products sold by COMPANY and its Affiliates after
the effective 
  
 [***] Certain information in this document has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 15 

 CONFIDENTIAL 

 

 
date of termination, COMPANY shall continue to make payments to Selexis in accordance with Section 3.1.3. 

 

	8.	CONFIDENTIALITY 

 8.1. Nondisclosure. During the Term, and for a period of five
(5) years thereafter, each Party will maintain all Confidential Information of the other Party as confidential and will not disclose any Confidential Information to any Third Party except to its Affiliates, sublicensees, employees, agents,
consultants and other representatives, who have a need to know such Confidential Information and who are bound by obligations of confidentiality at least as restrictive as set forth herein. Each Party may use such Confidential Information only to
the extent required to accomplish the purposes of this Agreement. Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own to ensure that its Affiliates, employees, agents,
consultants and other representatives do not disclose or make any unauthorized use of the Confidential Information. 
 8.2.
Exceptions. Confidential Information shall not include any information that the receiving Party can prove by competent evidence is: 

8.2.1. now, or hereafter becomes, through no act or failure to act on the part of the receiving Party, generally known or available; 

8.2.2. known by the receiving Party at the time of receiving such information, as evidenced by its records; 

8.2.3. hereafter furnished to the receiving Party by a Third Party, as a matter of right and without restriction on disclosure; 

8.2.4. independently developed by the receiving Party without the aid, application or use of Confidential Information; or 

8.2.5. the subject of a written permission to disclose provided by the providing Party. 

8.3. Authorized Disclosures. Each Party shall be permitted to disclose Confidential Information of the other Party: 

8.3.1. to the extent that, such Confidential Information is required to be disclosed to comply with applicable laws or regulations (such as
disclosure to the United States Securities and Exchange Commission or to comply with the request or order of any applicable Regulatory Authority, whether or not having the force of law) or with a court or administrative order; provided however, that
such Party shall first have given written notice of such required disclosure to the other Party, shall make reasonable efforts to narrow the scope of Confidential Information of the other Party required to be disclosed, and shall take reasonable
steps to allow the other Party at its own expense to seek a protective order to protect the confidentiality of the Confidential Information required to be disclosed; or 

  
 16 

 CONFIDENTIAL 

 

 8.3.2. to establish rights or enforce obligations under this Agreement, but only to the
extent such disclosure is necessary and provided that such Party seeks confidential treatment of the Confidential Information to be disclosed. 
  

	9.	MISCELLANEOUS 

 9.1. Assignment. Neither this Agreement nor any interest hereunder
shall be assignable by either Party without the prior written consent of the other Party; provided, that either Party may assign this Agreement and all of its rights and obligations hereunder, without such consent, to an entity which acquires all or
substantially all of the business or assets of such Party (or the business or assets to which this Agreement pertains) whether by merger, consolidation, reorganization, acquisition, sale, license or otherwise; and COMPANY may assign this
Agreement and all of its rights and obligations hereunder, without such consent, to an Affiliate if COMPANY remains liable and responsible for the performance and observance of all of the Affiliate’s duties and obligations hereunder.
This Agreement shall be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to
carry out the intent of this Agreement. Any assignment not in accordance with this Section 9.1 shall be null and void. 
 9.2.
Compliance with Governmental Obligations. Each Party shall comply, upon reasonable notice from the other Party, with all governmental requests directed to either Party and provide all information and assistance necessary to comply with the
governmental requests. 
 9.3. Counterparts. This Agreement may be executed in any number of counterparts, each of which need not
contain the signature of more than one Party but all such counterparts taken together shall constitute one and the same agreement, and may be executed through the use of facsimiles. 

9.4. Dispute Resolution. The Parties agree that in the event of a dispute between them arising from, concerning or in any way relating
to this Agreement, the Parties shall undertake good faith efforts to resolve any such dispute in good faith with the matter being referred at the request of either Party to the general counsel for each Party and, if remaining unresolved after thirty
(30) days, then to the chief executive officers of each Party (or their designees). If after ninety (90) days of the matter first being referred to the general counsel the Parties are unable to resolve such dispute, either Party may seek
any remedy available pursuant to Section 9.8 of this agreement 
 9.5. Entire Agreement. This Agreement (including the Exhibits
attached hereto, which are incorporated herein by reference) sets forth all of the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof;
constitutes and contains the complete, final, and exclusive understanding and agreement of the Parties with respect to the subject matter hereof; and cancels, supersedes and terminates all prior agreements and understanding between the Parties with
respect to the subject matter hereof. There are no covenants, promises, agreements, warranties, representations conditions or understandings, whether oral or written, between the Parties other than as set forth herein. No subsequent alteration,
amendment, change or addition 

  
 17 

 CONFIDENTIAL 

 

 
to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties. 

9.6. Force Majeure. Neither Party shall be liable to the other for loss or damages for any default or delay attributable to any Force
Majeure, if the Party affected shall give prompt notice of any such cause to the other Party. The Party giving such notice shall thereupon be excused from such of its obligations hereunder as it is thereby disabled from performing for so long as it
is so disabled, provided, however. that such affected Party commences and continues to take reasonable and diligent actions to cure such cause; and provided further that if any Force Majeure delays or prevents the performance of the obligations of
either party for a continuous period in excess of six months, the party not so affected shall then be entitled to give notice to the affected party to terminate this Agreement, specifying the date (which shall not be less than [30] days after the
date on which the notice is given) on which termination will take effect, Such a termination notice shall be irrevocable, except with the consent of both parties, and upon termination the provisions of Section 9.5 shall apply. 

9.7. Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as
may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. 
 9.8. Governing Law and
Jurisdiction. This Agreement shall be governed by and interpreted in accordance with the substantive laws of the State of Massachusetts. In relation to any legal action or proceedings arising out of or in connection with this Agreement
(“Proceedings”), each of the Parties irrevocably submits to the exclusive jurisdiction of the state and federal courts located in Boston, Massachusetts, and waives any objection to Proceedings in such courts on the grounds of venue
or on the grounds that Proceedings have been brought in an inappropriate forum. 
 9.9. Independent Contractors. The relationship
between Selexis and COMPANY created by this Agreement is one of independent contractors and neither Party shall have the power or authority to bind or obligate the other Party except as expressly set forth in this Agreement. 

9.10. Interpretation of Agreement. Article and other descriptive headings used in this Agreement are for reference purposes only and
shall not constitute a part hereof or affect the meaning or interpretation of this Agreement. Whenever the context so requires, the use of the singular shall be deemed to include the plural and vice versa. 

9.11. License Obligations. Nothing in this Agreement imposes any obligation upon a Party to enter into any other license or agreement
with the other Party. The Parties agree that (i) either Party shall be entitled, to the full extent permitted by applicable bankruptcy law, to elect to retain of its rights as a licensor or licensee respectively, in the event that the other
Party files for bankruptcy in any jurisdiction or has any petition for bankruptcy filed against it, and (ii) either Party may, to the fullest degree permitted by applicable bankruptcy law, exercise all of its rights and elections under the
relevant bankruptcy law, including but not limited to retention of its rights as a licensor or licensee respectively, regardless of whether either Party files for 

  
 18 

 CONFIDENTIAL 

 

 
bankruptcy in the United States or any other jurisdiction or has any petition for bankruptcy filed against it. 

9.12. Non-Disclosure. Except as otherwise required by law or regulation, and only after compliance with this Section 9.12, neither
Party shall issue a press release or make any other disclosure of the existence of or the terms of this Agreement, or otherwise use the name or trademarks or products of the other Party or the names of any employee thereof, without the prior
approval of such press release or disclosure by the other Party. However if, in the reasonable opinion of such Party’s counsel, a public disclosure shall be required by law, regulation, or court order, including without limitation in a filing
with the United States or Europe Securities and Exchange Commission or the United States Food and Drug Administration or the European Medicines Agency, the disclosing Party shall provide copies of the disclosure reasonably in advance of such filing
or other disclosure for the non-disclosing Party’s prior review and comment, and the non-disclosing Party shall provide its comments as soon as practicable. No disclosure permitted by this Section 9.12 shall contain any Confidential
Information of the other Party unless otherwise permitted in accordance with Section 9 herein. 
 9.13. Notices. All notices and
other communications required by this Agreement shall be in writing in the English language and shall be deemed given if delivered personally or by facsimile transmission (receipt verified), mailed by registered or certified mail (return receipt
requested), postage prepaid, or sent by express courier service, to the Parties at the following addresses (or at such other address for a Party as shall be specified by like notice, provided, however, that notices of a change of address shall be
effective only upon receipt thereof): 
  

					
	 	  	 To Company
	  	 Selexis

			
	Address:	  	BioGenerics, Inc.	  	Selexis S.A.
		  	555 Bryant St Ste 266	  	18 Chemin des Aulx
		  	Palo Alto, CA 94301	  	1228 Plan-les-Ouates
		  		  	Geneva, Switzerland
			
	Attention:	  	Chief Executive Officer	  	General Assistant
			
	With a copy to:	  	Chief Business Officer	  	Chief Executive Officer
	Facsimile:	  	+1 650 521-5910	  	+41 22 308-9361

 or to such addresses or addresses as the Parties hereto may designate for such purposes during the Term. Notices shall be
deemed to have been sufficiently given or made: (i) if by facsimile with confirmed transmission, when performed, and (ii) if by air courier upon receipt by the Party. 

9.14. Parties in Interest. This Agreement shall be binding upon and inure solely to the benefit of COMPANY and Selexis (and
their permitted successors and assigns) and nothing in this Agreement (express or implied) is intended to or shall confer upon any Third Party any rights, benefits or remedies of any nature whatsoever under or by reason of this Agreement. 

  
 19 

 CONFIDENTIAL 

 

 9.15. Severability. If any term, covenant or condition of this Agreement or the
application thereof to any Party or circumstance shall, to any extent, be held to be invalid or unenforceable, then the remainder of this Agreement, or the application of such term, covenant or condition to parties or circumstances other than those
as to which it is held invalid or unenforceable, shall not be affected thereby and each term, covenant or condition of this Agreement shall be valid and be enforced to the fullest extent permitted by law. 

9.16. Use of Name. No right, express or implied, is granted to either Party by this Agreement to use in any manner any trademark or
trade name of the other Party including the names “BioGenerics” and “Selexis” without the prior written consent of the owning Party. 

9.17. Waiver. The failure on the part of a Party to exercise or enforce any rights conferred upon it hereunder shall not be deemed to
be a waiver of any such rights nor operate to bar the exercise or enforcement thereof at any time or times hereafter. 

  
 20 

 CONFIDENTIAL 

 

 In Witness Whereof, the Parties, having read the terms of this Agreement and intending to be
legally bound hereby, do hereby execute this Agreement. 
  

			
	SELEXIS S.A.
		
	By:	 	 /s/ Igor Fisch

	Name: Dr. Igor Fisch
	Title: CEO
	Date: April 13, 2014
		
	By:	 	 /s/ Regine Brokamp

	Name: Regine Brokamp
	Title: COO
	Date: April 13, 2014
	
	COMPANY
		
	By:	 	 /s/ Dennis M. Lanfear

	Name: Dennis M. Lanfear
	Title: President and CEO
	Date: April 8, 2014

  

 CONFIDENTIAL 

 

 EXHIBIT 1 

SELEXIS PATENT RIGHTS 
 Patent 1. 

 

			
	Title	 	[***]
		
	Priority date	 	[***]
		
	Priority ID	 	[***]
		
	Publication ID	 	[***]
		
	Geographies	 	[***]
		
	Status	 	[***]

 Patent 2. 
  

			
	Title	 	[***]
		
	Priority date	 	[***]
		
	Priority ID	 	[***]
		
	Publication ID	 	[***]
		
	Geographies	 	[***]

  
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]